CLINICAL_TRIALS
trial_result
· 2018-05-14
Clinical Trial Update: Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer [Phase 2]
Summary
Phase 2 trial update on exisulind with intermittent androgen suppression in biochemical relapsed prostate cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Washington | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-05-14